ChronoScale Targets $1B Revenue Run-Rate and Completes Ekso Bionics Sale
Key Facts
ChronoScale announced new agreements expected to drive its annualized revenue run rate to $1 billion by the third quarter of 2027. According to a company statement on GlobeNewswire, these contracts involve expanding the scale of its AI infrastructure deployments and strengthening contracted revenues.
The company also completed the previously disclosed sale of its Ekso Bionics business unit, as ChronoScale focuses on its accelerated compute platform purpose-built for AI workloads. This strategic shift comes as the firm seeks to expand customer relationships and scale its deployment pipeline.
Latest Updates · 1
- Notable·
Update: ChronoScale stock rose in recent trading following the announcement of its billion-dollar revenue targets linked to AI infrastructure deals. This price movement reflects positive investor sentiment toward the company's new strategy following the divestment of its Ekso Bionics unit.